Document:

<PAGE>   1

EXHIBIT 10.1

                              EMPLOYMENT AGREEMENT

                  THIS AGREEMENT made as of the 8th day of January, 2000 by and
between Nymox Pharmaceutical Corporation, a Canadian corporation (the
"Company"), and Judith Fitzpatrick (the "Executive").

                             W I T N E S S E T H :

WHEREAS the Company is this day purchasing from the Executive all of her common
shares of Serex, Inc., a New Jersey corporation, and thereby acquiring a
controlling interest in Serex, Inc.;

WHEREAS, the Executive is this day receiving 187,951 shares of the common stock
of the Company and a warrant to purchase 115,662 shares of the common stock of
the Company as consideration for the purchase of her Serex common stock, subject
to the terms of the Share Purchase Agreement between the Company and the
Executive;

WHEREAS, the Company wishes to retain the services of the Executive as a
Vice-President of the Company to continue her development work on the Company's
7C Gold test and to continue to direct the scientific endeavors of Serex Inc.
and to act as President of Serex, Inc.;

WHEREAS, the Executive wishes to provide her services to the Company on the
terms set out below in this Employment Agreement and acknowledges that the
Company is reasonably relying upon Executive's execution of this Agreement as
part of its decision to purchase her shares of Serex, Inc.;

NOW, THEREFORE, in consideration of the covenants and agreements of the parties
herein contained, and as an inducement to the Company to close the purchase of
the Executive's shares of Serex, Inc., the Company and the Executive agree as
follows:

1.       Employment.

The Company hereby employs the Executive and the Executive hereby accepts
appointment as Vice-President of the Company. The Executive agrees to remain in
the employment of the Company on the terms and conditions set out below in this
Agreement. Paragraph 6 of this Agreement sets out the Executive's duties.

2.       Term.

The initial term of this Employment Agreement shall be four years, commencing on
January 8th, 2000 and expiring on January 8th, 2004 unless terminated earlier
pursuant to paragraph 13 below or extended as provided in this paragraph. At the
end of the initial term of the Agreement (or the end of the term of any
automatic renewal of this Agreement), the term of this Agreement shall be
automatically renewed for an additional term of one year unless either the
Company or the Executive gives the other party notice at least 30 days prior to
the end of the term of its/her intention not to renew the Agreement.

                                      E-86

<PAGE>   2

3.       Salary and Other Compensation.

(a)      As part of the Executive's compensation for services to be rendered
under this Agreement, the Company shall pay the Executive an annual salary at
the rate of One Hundred and Twenty-five Thousand Dollars ($125,000) (as adjusted
upward at the discretion of the Compensation Committee of the Board of Directors
of the Company from time to time) payable, as nearly as practicable, in equal
semimonthly installments. The Company agrees to review the Executive's salary at
least once in every year during the term of this Agreement and adjust it upward
accordingly in order to ensure that the Executive's salary is always more than
any other employee under her supervision. The Executive's salary, once
increased, shall not be later reduced.

(b)      [Confidential]

4.       Options.

Further as part of the Executive's compensation, the Company shall grant the
Executive an option to purchase at any time or from time to time after their
vesting dates and on or before December 23, 2009 (the "Expiry Date") 40,000
common shares of the Company in accordance with the Nymox Share Option Plan, a
copy of which is attached to and forms part of this Agreement as Schedule A (the
"Option Plan"). At the Expiry Date, the option hereby granted and still in
effect shall expire and terminate and be of no further force or effect as to the
optioned shares in respect of which the option hereby granted has not been
exercised.

The exercise price of each option shall be $3.70 per share, vesting as follows:

          - 10,000 on the first anniversary of the date of this Employment
            Agreement;

          - 10,000 on the second anniversary of the date of this Employment
            Agreement;

          - 10,000 on the third anniversary of the date of this Employment
            Agreement; and

          - 10,000 on the fourth anniversary of the date of this Employment
            Agreement.

In the event that options granted to other executives or officers of the Company
are repriced or otherwise adjusted downward in the future, the options granted
the Executive under this Agreement shall be afforded the same proportionate
treatment on a percentage-wise basis as those treated most favorably pursuant to
the repricing or other adjustments.

                                      E-87

<PAGE>   3

5.       Additional Benefits and Reimbursement of Expenses.

5.1      The Company shall provide the following additional benefits to the
         Executive during the term of this Agreement:

         (i)    20 working days of paid vacation per year (non-cumulative);

         (ii)   up to 10 paid sick days per year (non-cumulative);

         (iii)  5 paid days per year for attendance at scientific conferences,
                professional, industry and investigator conferences and studies
                of the Executive's choice (non-cumulative);

         (iv)   health care benefits, either in the form of a $5,000 health care
                allowance or coverage under the Company's health care plan; and

         (v)    such other benefits as the Company's Board shall lawfully adopt
                and approve for the Executive.

5.2      The Company shall pay or reimburse the Executive for all reasonable
         expenses actually incurred by the Executive or paid by the Executive
         during the term of the Agreement for expenses in connection with
         Company business, including:

                - travel expenses, including air and rail fare and, when
                  overnight stay is required, hotel accommodation and personal
                  meals (meals not exceeding $50.00 per day);

                - telephone expenses, including long distance calls from
                  personal phones; and

                - office supplies including stationary but not including office
                  equipment.

         Expense claims are payable upon timely presentation of an expense
         report together with such bills, expenses, statements, vouchers or such
         other supporting information as the Company may reasonably require.

6.       Duties.

The duties of the Executive shall include:

         - participation on a scientific basis with the Company's research and
           development work on drugs for the prevention, treatment and delay of
           onset of Alzheimer's disease, antimicrobial treatments and other
           therapeutic and scientific projects;

         - continuing scientific, regulatory and commercial development of the
           Company's 7C Gold Test for Alzheimer's disease;

         - scientific, regulatory and commercial development of the diagnostic
           projects of the Company and of Serex, Inc.;

         - acting as the President of Serex, Inc.;

                                      E-88

<PAGE>   4

         - directing the scientific endeavors of Serex, Inc.;

         - the management and development of Serex, Inc.'s ongoing research,
           product development, intellectual property, and technologies,
           including its proprietary SARA technology and its ongoing development
           of diagnostic assays; and

         - attendance at scientific conferences, professional, industry and
           investigator conferences and studies at the Company's request.

The Executive shall report to the President and C.E.O. of the Company and/or a
delegate to be appointed from time to time. The President and C.E.O. of the
Company may change these duties or assign new duties to the Executive from time
to time not inconsistent with the terms of this Agreement. The Executive agrees
to devote her full business time and effort to the diligent and faithful
performance of such duties.

7.       Place of Employment.

The Executive's principal place of employment shall be in the Maywood, New
Jersey area and the Company shall not relocate her principal place of employment
to a new location more than 50 miles from Maywood, New Jersey without her prior
written approval. The Executive acknowledges that her duties may require her
traveling to Montreal on a regular basis and other traveling as a necessary
incident of her employment.

8.       Confidentiality.

(a) The Executive acknowledges that during the course of her employment with the
Company she may have access to confidential and/or proprietary technical,
scientific or business information relating to the Company's research, product
development, marketing, sales, services, financing and other business or
scientifically related activities and that it is vital to the Company to
preserve the confidentiality of its technical, scientific and business affairs
and to maintain its intellectual properties, including trade secrets, know-how
and patent applications.

(b) Accordingly, as a condition of the Executive's employment, the Company and
the Executive agree as follows:

         1.  In this Agreement,

                  "Confidential Information" means any information or data
                  relating to, arising out of or in connection with the
                  research, technology, intellectual property, know-how,
                  improvements, equipment, formulas, designs, processes, product
                  development, packaging, products, distribution methods,
                  marketing, customers, financing and/or business of the
                  Company;

                                      E-89

<PAGE>   5

          "Company" means Nymox Pharmaceutical Corporation, Nymox Corporation
and their affiliates and includes their successors and assigns;

          "Company Property" means any property owned by the Company and
includes (but not limited to):

                           (a) laboratory equipment, reagents, samples,
                           specimens, standards, protocols, requisitions, test
                           results, drug candidates, cell lines, notebooks,
                           papers, presentations and publications;

                           (b) computer equipment, software, files, disks,
                           cd-roms, tapes and all other electronic means of
                           storing data or information;

                           (c) cell phones, pagers, answering machines,
                           telephones and other telecommunication equipment;

                           (d) office equipment, office furniture,
                           correspondence, memoranda, reports, faxes, files,
                           books, magazines, stationary, messages, e-mails,
                           contracts, patent documents, customer lists, supplier
                           lists, brochures, marketing material, displays,
                           posters and financial reports; and

                           (e) credit cards, calling cards, bank cards,
                           checkbooks, deposit books, bank statements, financial
                           records, canceled checks, receipts, invoices, bills
                           and accounts.

         2. The Executive shall keep in strict confidence any Confidential
         Information and not to disclose it to any third party except as
         required by law, regulation, legal process or other governmental
         authority, as permitted this Agreement or with the written consent of
         the President of the Company.

         3. The Executive shall take reasonable care to maintain all
         Confidential Information in confidence and shall inform the Company
         immediately upon the discovery of any unauthorized disclosure or use of
         any Confidential Information and take reasonable steps to prevent any
         further unauthorized disclosure or use.

         4. The Executive shall not use any Confidential Information for any
         purpose other than the performance of her/his duties as an officer and
         employee of the Company.

         5. Confidential Information shall not include information which:

         (i)   was known to the Executive prior to receipt by Executive of any
               Confidential Information hereunder;

         (ii)  was known or has become known to the public through lawful
               disclosure; or

         (iii) a third party having the right to disclose such information has
               lawfully disclosed such information to the Executive.

                                      E-90

<PAGE>   6

9.       Company Property.

(a)      The Executive acknowledges and agrees that the Company owns completely

         (i)      all past, present and future patent rights, trade secrets,
                  know-how, copyright, trademarks, industrial designs and other
                  intellectual property rights related to, connected with or
                  arising out of scientific projects undertaken at or by the
                  Company or funded by the Company, and

         (ii)     all patent, trademark, copyright, trade secrets, know-how,
                  industrial designs and other intellectual property rights to
                  scientific, research and development or commercial work
                  already performed, being performed or to be performed in the
                  future by the Executive in the course of or during the term of
                  her employment at the Company.

(b) The Executive agrees to disclose to the Company in a timely manner any
inventions, discoveries, ideas or research findings, whether patentable or not,
relating to, connected with or arising out of her employment with the Company or
related to or connected with the business of the Company.

(c) The Executive agrees to assign completely, exclusively and irrevocably to
the Company any and all rights, interests and title to any inventions,
discoveries and ideas, whether patentable or not, (including, but not limited to
patent applications, patents, trademarks, copyrights, trade secrets, know-how,
industrial designs, or other intellectual property rights) relating to,
connected with or arising out of her employment with the Company, related to or
connected with the business of the Company, or conceived or reduced to practice
at any time during the Executive's employment by the Company, either solely or
jointly with others and whether or not developed on the Executive's own time or
with the resources of the Company.

The Executive further agrees, on request by the Company, both during the term of
her employment with the Company and after termination of that employment, to
execute any patent, copyright, trademark, trade secrets or industrial design
assignments, applications, certificates, affidavits or other documents that, in
the opinion of the Company, are necessary to secure, protect or evidence the
Company's intellectual property rights.

 (d) The Executive shall not use Company Property except for the purposes of
employment or as otherwise authorized. The Executive shall not, except for the
Company's use, copy or duplicate any Company documents or property, nor remove
them from the Company's facilities, nor use any information concerning them
except for the Company's benefit, either during her employment or thereafter.

(e) Upon the Company's request or upon termination of employment, the Executive
shall promptly:

         (i)      return any Confidential Information that is in tangible form
                  and any Company Property in her possession or under her
                  control without making or retaining any copies; and

                                      E-91

<PAGE>   7

         (ii)     provide any passwords to computer files, systems or networks
                  or codes for any research or clinical trials used by the
                  Executive in the course of her employment.

(f) Nothing in this Employment Agreement shall be construed as transferring,
assigning or conveying to the Company any rights, interests and title to any
inventions, discoveries, patent applications, patents, trademarks, copyrights,
trade secrets, know-how, industrial designs, or other intellectual property
rights that the Executive and/or Serex, Inc. had prior to the date of this
Agreement, other than those intellectual property rights and interests relating
to the Company's AD7C(TM) test.

10.      Conflicts of Interest.

(a)      During the term of her employment with the Company, the Executive
         agrees:

         (i)      not to engage in any other employment or business or act as an
                  officer or director of or consult with any other company,
                  business or person, other than a non-profit corporation or
                  organization, except with the prior approval of the President
                  of the Company, which approval will not be unreasonably
                  withheld;

         (ii)     to promptly disclose to the President of the Company any
                  business opportunities that come to the attention of the
                  Executive and that relate to the pharmaceutical or diagnostic
                  business, including (but not limited to) research proposals,
                  licensing opportunities, patent applications and assignments,
                  co-marketing ventures, technology transfers and employment
                  opportunities.

(b) The Executive agrees that, during the term of her employment and for one
year after the date of termination of employment unless such termination is
pursuant to paragraphs 13(a)(iv) or 13(a)(v), she will not, directly or
indirectly, own, manage, operate, control or participate in the ownership,
management, operation or control of, or be connected as an officer, executive,
partner, director or otherwise with, or have any financial interest in, or aid
or assist anyone else in the conduct of, any business that markets a diagnostic
for Alzheimer's disease or that is substantially similar to or competitive with
the Company's present business or any other business at which the Company may
substantially engage during the term of the Executive's employment, provided,
however, that the Executive may own not more than 4.9% of the equity securities
of a corporation, trading on a public stock exchange .

(c) The Executive further agrees that, during the term of her employment and for
one year after the date of termination of employment, she will not solicit or
assist, directly or indirectly, any employee of the Company to terminate his or
her employment with the Company or to divert any intellectual property, trade
secrets, business or customers from the Company.

(d) The Executive agrees that all restrictions in this article are reasonable,
valid and do not go beyond what is necessary to protect the interests of the
Company, and waives all defenses to their strict enforcement. The Executive
acknowledges that the market for diagnostic tests and kits and for therapeutic
drugs that the Company is presently marketing and/or developing is worldwide and
that any specific geographic restriction in this article would be unenforceable.

                                      E-92

<PAGE>   8

(e) The provisions of this article are only intended to safeguard against the
Executive participating in competitive endeavors against the Company and shall
not in any way restrict or limit the Executive from engaging in, employment by
or consulting with subsequent businesses which are not in direct competition
with the Company. In particular, the Executive may engage in the development of
immunoassays, strip assays and diagnostic kits that are not designed to detect a
unique or proprietary marker for any condition for which the Company was
developing diagnostic tests, kits or assays during the term of her employment.

(f) The parties agree that if any covenant or provision in this article is
determined to be void or unenforceable at law due to period of time,
geographical area, or otherwise, then such covenant or provision shall be
reduced in scope or amended, as to term, geographical area or otherwise, to the
extent required so that the covenant or provision, as so reduced or amended, is
enforceable at law and the unenforceable part shall be deemed to be severed from
the balance, which balance shall survive and be of full force and effect.

11.      Communications.

(a) The Executive agrees that the Company may treat any communications
(including, but not limited to, mail, telephone messages, e-mail messages and
voice mail) or item (including, but not limited to, reagents, specimens, and
samples) addressed to the Executive and received at one of the Company's
offices, laboratories or research facilities or through its e-mail, voice mail
or other telecommunication systems as a communication or item relating to,
arising out of or in connection with the Company's business and may open, review
and/or inspect the communication or item in order to determine, in its sole
discretion, whether the communication or item relates to, arises out of or is
connected with Nymox's business. If the Company so determines, then the Company
may retain and use the communication or item as it sees fit.

(b) The Executive agrees not to release or disclose to any third party any
publications, presentations or press releases relating to, arising out of or in
connection with the Company's business, research and development, technology or
collaborations with other researchers, institutions or businesses without the
prior approval of the President of the Company.

12.      Provisions Which Survive the Termination of this Agreement.

The provisions of this Agreement contained in Articles 8 (Confidentiality), 9
(Company Property), 10 (Conflicts of Interest) and 11 (Communications) shall
survive the termination of the Executive's employment.

                                      E-93

<PAGE>   9

13.      Termination of Employment.

(a) The Executive's employment shall terminate, or be subject to termination,
prior to the term specified in Article 2 hereof, as follows:

         (i) The Executive's employment shall terminate upon death.

         (ii) If, during the term of this Agreement, the Executive has a
         Disability, the Company may, at any time after the Executive has a
         Disability, terminate the Executive's employment by written notice to
         her. In the event that the Executive's employment is terminated, this
         Agreement shall terminate except that the Company shall continue to pay
         the Executive's salary for a period of six (6) months from the date of
         termination of her employment and maintain her health care benefits for
         the balance of the term of this Agreement, as if the Executive had not
         been terminated for Disability. As used in this Agreement, "Disability"
         shall mean the inability of the Executive to perform the Executive's
         duties of employment for the Company, pursuant to the terms of this
         Agreement, because of physical or mental disability, where such
         disability shall have existed for a period of more than 90 consecutive
         days or an aggregate of 120 days in any 365-day period. The existence
         of a Disability means that the Executive's mental or physical
         disability substantially interferes with the performance of her
         substantive duties for the Company as specified in this Agreement. The
         fact of whether or not a Disability exists hereunder shall be
         determined by professionally qualified medical experts selected by the
         Board and reasonably acceptable to the Executive or her agent.

         (iii) The Company may, at any time, terminate the Executive's
         employment for cause. For the purposes of this Agreement, the Company
         shall have cause to terminate the Executive's employment hereunder
         upon:

                  (A) the Executive engaging in misconduct which is injurious to
                  the Company;

                  (B) any material breach of this Agreement by the Executive
                  that is not cured by the Executive within thirty (30) days
                  after the Company has given the Executive written notice
                  specifying the particulars of the breach of the Agreement and
                  its intent to terminate her employment if the breach is not
                  cured; or

                  (C) the Executive's conviction of a felony or a plea by the
                  Executive of nolo contendere to a felony.

         (iv) The Company may terminate the Executive's employment without cause
         upon forty-five (45) days prior written notice to the Executive or upon
         payment of forty-five days salary in lieu of notice. Termination of the
         Executive's employment by the Company for any reason, other than
         specified in paragraphs 13(a)(i), (ii) or (iii) shall constitute
         termination of this Agreement without cause.

         (v) The Executive may terminate her employment for Good Reason upon
         forty-five (45) days prior written notice to the Company. If the
         Executive's employment is terminated pursuant to this Section,
         13(a)(v), the Executive shall be entitled to receive those severance
         payments and other benefits as if the Executive was terminated pursuant
         to Section 13(a)(iv) of this Agreement. Good Reason means:

                                      E-94

<PAGE>   10

                  (A) the assignment by the Company to the Executive of duties
                  which are materially different than those of the Vice
                  President of the Company as described in Article 6 of this
                  Agreement, where the Company has not resolved the Executive's
                  objections to the assignment within sixty (60) days after
                  written notice from the Executive specifying her objections to
                  the assignment and her intent to terminate her employment on
                  that ground if not resolved to her reasonable satisfaction;
                  and

                  (B) any material breach of this Agreement by the Company that
                  is not cured by the Company within thirty (30) days after the
                  Executive has given the Company written notice specifying the
                  particulars of the breach of the Agreement and her intent to
                  terminate her employment if the breach is not cured.

(b) In the event of the termination of the Executive's employment pursuant to
paragraphs 13(a)(iv) or 13(a)(v), the Executive shall be entitled to receive, in
lieu of any other compensation or payment as a result of such termination,
severance payments in an amount equal to the lesser of twelve months of the
Executive's salary and all other benefits provided to the Executive under this
Agreement at the time of termination or the balance of that salary remaining on
the term of this Agreement and all other benefits provided to the Executive
under this Agreement. The severance payments will be payable, as nearly as
practicable, in equal semimonthly installments and shall cease in the event the
Executive finds new employment in the pharmaceutical or diagnostic industry.
During the severance payment period, the Executive agrees to comply with the
provisions of paragraph 10(b).

(c) In the event of the termination of the Executive's employment, all payments
of salary and benefits under Articles 3 and 5 of this Agreement, other than
payments of salary or benefits owed or accruing to the Executive prior to the
termination, shall cease, and the Executive shall not be entitled to receive any
compensation, benefits or payment on account of such termination, except as
otherwise provided in paragraphs 13(a)(ii) and 13(b). The Executive shall be
entitled to receive those benefits which by their terms continue after
termination of employment in accordance with the terms of such benefits
applicable after termination of employment as required by applicable law.

14.      Miscellaneous.

(a)      Notices

Any notice or other communication required by this Agreement shall be in writing
and shall be effective if hand delivered or if sent by certified or registered
mail or by facsimile transmission to the following locations until notified
otherwise in writing.

Nymox Pharmaceutical Corporation

                  Attention: President
                  Nymox Pharmaceutical Corporation
                  9900 Boul. Cavendish, Suite 306
                  Saint Laurent, Quebec, Canada, H4M 2V2
                  FAX: (514) 332-2227

                                      E-95

<PAGE>   11

The Executive:

                  Judith Fitzpatrick Davis
                  c/o Serex, Inc.
                  230 West Passaic Street
                  Maywood, New Jersey
                  FAX:     201-368-7850

A notice is effective on the date of delivery to the Party. Delivery is deemed
to have occurred on the day of delivery by courier, or upon facsimile
transmission with confirmation, or on the fifth day after the date of sending
the notice by registered mail.

(b)               Governing Law

This Agreement shall be interpreted and enforced in accordance with the
substantive laws of the State of New Jersey. The Executive acknowledges that her
violation, or threatened violation, of the provisions of Articles 8
(Confidentiality), 9 (Company Property), 10 (Conflicts of Interest) and 11
(Communications) would cause the Company irreparable injury and, in addition to
any other remedies to which the Company may be entitled, the Company shall be
entitled to immediate injunctive relief in addition to any remedy available
through the arbitration procedures set out below in paragraph 14(c).

(c)               Dispute Resolution

In the event of any controversy or claim arising out of or relating to any
provisions of this Agreement or the breach thereof, the Parties shall try to
settle those conflicts amicably between themselves. Should they fail to agree,
the matter in dispute shall be settled through arbitration conducted by and in
accordance with the rules of the American Arbitration Association ("A.A.A.").

Either Party may furnish the other party with a dated, written notice (the
"Arbitration Notice") indicating (i) intent to commence arbitration proceedings,
(ii) the nature, with reasonable detail, of the dispute, (iii) the amount
involved, if any, and (iv) the remedy sought. The arbitration shall be held at a
neutral place mutually agreeable to the parties. Within thirty (30) days of the
date of the Arbitration Notice, each party shall select one (1) Arbitrator, who
shall not be a current or former employee, agent, consultant or other
representative of either party; the two selected Arbitrators shall appoint a
third, neutral, Arbitrator.

The arbitration award shall be final and binding. Either party may enter any
such award in a court of the State of New Jersey having jurisdiction or may make
application to such court for judicial acceptance of the award and an order of
enforcement, as the case may be.

(d)               Currency

All references to money in the Agreement refer to U.S. dollars and all payments
made under this Agreement shall be in that currency.

                                      E-96

<PAGE>   12

(e)               Partial Invalidity

If any provision of this Agreement be held invalid, illegal or unenforceable,
such invalidity, illegality or unenforceability shall not affect any other
provision of this Agreement and the Parties shall use reasonable efforts to
substitute a valid, legal and enforceable provision which, as far as
practicable, implements the purposes and intent of the provision held invalid,
illegal or unenforceable. If the Parties are unable to arrive at such a
substitute, this Agreement shall be construed as if such invalid, illegal or
unenforceable provision had never been contained in it, provided that the
performance required under this Agreement with such a provision deleted remains
substantially consistent with the intent of the Parties.

(f)               Waiver

Failure to require performance of any provision of this Agreement does not waive
a Party's right to demand compliance with that provision at a later time. Waiver
of any default shall not waive any other default.

(g)               Entire Agreement

This Agreement contains the entire agreement between the Parties with respect to
the subject matter covered by this Agreement. No representations, whether oral
or written, made before this Agreement is executed shall amend this Agreement.
Any modification or amendment to this Agreement shall be in writing and signed
by an authorized officer of each Party.

(h)               Inurement

This Agreement shall be binding upon and shall inure to the benefit of the
Company and the Executive and their respective heirs, successors, assigns,
permitted receivers and legal representatives.

(i)               Language

The Company and the Executive have expressly requested that this Agreement and
any agreement, proceedings or documents thereto or referred to therein be
drafted and executed in the English language. Nymox et le Consultant ont
expressement exige que ce contrat ainsi que tous contrats, procedures ou
documents s'y rapportant ou qui y sont mentionnes soient rediges et signe en
langue anglaise.

IN WITNESS THEREOF, the undersigned have executed this Agreement as of the dates
set forth below:

ACCEPTED AND AGREED TO:
Nymox Pharmaceutical Corporation                     The Executive

/s/ Paul Averback                                    /s/ Judith Fitzpatrick
--------------------------------                     ---------------------------
Paul Averback                                        Judith Fitzpatrick
President

                                      E-97<PAGE>   1
                                                                    Exhibit 10.7

                SHARE EXCHANGE AND REGISTRATION RIGHTS AGREEMENT

         SHARE EXCHANGE AND REGISTRATION RIGHTS AGREEMENT dated as of December
16, 1999 between Aetna Inc., a Connecticut corporation (the "COMPANY") and
Citibank, N.A. ("Citibank").

                                    WHEREAS,

       Citibank has entered into the Loan Agreement with Ta Hsing, which Loan
Agreement is secured in part by a pledge of 20% of the shares of ALICA Holdings,
Inc., a Connecticut corporation that owns all of the non-voting shares of common
stock of Aetna Life Insurance Company of America ("ALICA");

         Aetna International, Inc. ("AII"), a subsidiary of the Company, owns
the remaining shares of ALICA and ALICA Holdings;

       In order to assist Ta Hsing in obtaining the loan evidenced by the Loan
Agreement, AII has consented to the pledge by Ta Hsing of Ta Hsing's shares of
ALICA Holdings in favor of Citibank and the Company has agreed to enter into
this Agreement.

In consideration of the foregoing and the agreements contained herein, the
parties agree as follows.

                                    ARTICLE I

                                   DEFINITIONS

         SECTION 1.01. Definitions. The following terms, as used herein, have
the following meanings:

       "1933 ACT" means the Securities Act of 1933, as amended, and the rules
and regulations thereunder.

       "1934 ACT" means the Securities Exchange Act of 1934, as amended and the
rules and regulations thereunder.

       "AII" has the meaning ascribed to it in the preambles to this Agreement.

       "ALICA" has the meaning ascribed to it in the preambles to this
Agreement.

       "ANCILLARY AGREEMENT" OR "ANCILLARY AGREEMENTS" means all other documents
entered into between Ta Hsing and Citibank in connection with the Loan
Agreement, including, without limitation, a share mortgage relating to the
Collateral.
<PAGE>   2
       "BUSINESS DAY" means any day except a Saturday, Sunday or other day on
which commercial banks in either of the States of New Jersey or New York are
authorized by law to close.

       "COLLATERAL" means the 20% of the shares of common stock of ALICA
Holdings, Inc., a Connecticut corporation, owned by Ta Hsing and pledged under a
share mortgage to secure payment of the loan under the Loan Agreement.

       "COLLATERAL VALUE" has the meaning ascribed to it in Section 2.05.

       "COMMISSION" means the Securities and Exchange Commission.

       "COMMON STOCK" means the Company's Common Stock, par value $0.01 per
share.

       "COMPANY'S 1999 FORM 10-Q" means the Company's quarterly report on Form
10-Q as filed with the Securities and Exchange Commission pursuant to the
Securities Exchange Act of 1934, as amended.

       "CONSOLIDATED SUBSIDIARY" means, at any date, any Subsidiary or other
entity the accounts of which would be consolidated with those of the Company in
its consolidated financial statements if such statements were prepared as of
such date.

       "LENDER DEFAULT AMOUNT" means the sum of all unpaid principal, accrued
interest, costs and other amounts due and owing to Citibank by Ta Hsing under
the Loan Agreement from time to time and as certified by Citibank (whose
certification shall be conclusive and binding on the Company and Citibank in the
absence of demonstrable error) following the occurrence of an Event of Default
as defined in the Loan Agreement.

       "LOAN AGREEMENT" means that certain revolving credit facility in the
original principal amount of US $154 million between Citibank and Ta Hsing dated
or to be dated 17 December 1999.

       "MINIMUM VALUE" has the meaning ascribed to it in Section 2.05.

       "PERSON" means an individual, a corporation, a partnership, a limited
liability company, an association, a trust or other entity or organization,
including a government or political subdivision or an agency or instrumentality
thereof.

         "PIGGYBACK REGISTRATION" means a Piggyback Registration as defined in
Section 3.02.

       "REGISTRABLE SECURITIES" means all shares of Common Stock issued to
Citibank or its nominee upon the exercise by the Company of the right to issue
shares of Common Stock contained in Section 2.01 of this Agreement.

         "SHELF REGISTRATION STATEMENT" means the Shelf Registration Statement
as defined in Section 3.01.

                                       2
<PAGE>   3
       "SUBSIDIARY" means any corporation or other entity of which securities or
other ownership interests having ordinary voting power to elect a majority of
the board of directors or other persons performing similar functions are at the
time directly or indirectly owned by the Company.

       "TA HSING" means Ta Hsing Corp. Limited, a Liberian company controlled by
Dr. Samuel Yin.

       "UNDERWRITER" means a securities dealer who purchases any Registrable
Securities as principal and not as part of such dealer's market-making
activities.

                                    ARTICLE 2

                              SHARE EXCHANGE RIGHTS

SECTION 2.01 Aetna Options on Event of Default. If any Event of Default, as
defined in the Loan Agreement or any Ancillary Agreement, shall occur and be
continuing under circumstances in which Citibank has the right to exercise its
power of sale in respect of the Collateral, then Citibank shall promptly after
becoming aware of the same so notify the Company and certify the Lender Default
Amount to the Company. Upon receipt of notice from Citibank that Citibank has
elected to exercise such power of sale, the Company shall be obliged forthwith
to pay Citibank or its nominee in full the Collateral Value, but not to exceed
Lender Default Amount, which it may do in one or a combination of the following,
such combination being chosen at the discretion of the Company:

         (a)      Cash in immediately available funds wired to an account
                  designated in writing by Citibank;

         (b)      Registrable Securities, determined in accordance with Section
                  4.03.

Provided that, to the extent that payment is made in whole or in part by
Registrable Securities, the Lender Default Amount shall not be reduced and shall
continue to accrue interest and/or default interest under the Loan Agreement
until the Registrable Securities are sold and the proceeds of such sale applied,
as described in Sections 2.03 and 3.04.

SECTION 2.02 Transfer of Collateral to Aetna In exchange for and in
consideration of the Company's payment(s) to Citibank or its nominee described
in Section 2.01, concurrently with such payment(s), Citibank or its nominee
shall immediately exercise its power of sale in favour of AII in respect of all
of the Collateral.

SECTION 2.03 Citibank Rights on Receipt of Shares If the Company shall issue
Registrable Securities to Citibank or its nominee under Section 2.01, then
Citibank or its nominee shall have the right to sell such Registrable Securities
under the following terms:

                                       3
<PAGE>   4
       (a)    If the Company provides Citibank or its nominee with an opinion of
              reputable outside counsel that the Registrable Securities may
              immediately be sold under SEC Rule 144 or any successor rule, then
              Citibank or its nominee shall be required to sell such number of
              Registrable Securities as may then be sold pursuant to Rule 144
              and may not exercise the rights set forth in Article 3 of this
              Agreement with respect to such Registrable Shares.

       (b)    If the Company is unable to or does not provide Citibank or its
              nominee with such an opinion as to any or all of the Registrable
              Securities, then Citibank or its nominee may exercise the rights
              set forth in Article 3 with respect to the Registrable Securities
              that are not subject to immediate sale pursuant to the opinion
              received pursuant to Section 2.03(a) above by giving written
              notice to the Company of its intent to exercise such rights.

Citibank or its nominee shall sell all the Registrable Securities that may be
immediately sold promptly after receipt of the opinion referenced in Section
2.03(a) above, and shall apply the proceeds of any such sale in or towards
satisfaction of the Lender Default Amount. Where the proceeds of such sale
exceed the Lender Default Amount, Citibank will promptly pay such excess amount
to the Company in cash in immediately available funds and return to the Company
any residual Registrable Securities held by Citibank or its nominee. If the
proceeds of such sale are less than the Lender Default Amount, the Company will
proceed with the registration as provided in Article 3 below, provided that if
all Registrable Securities have been sold by Citibank or its nominee then
promptly following receipt of a certificate from Citibank or its nominee stating
the amount of the shortfall (which certificate shall be binding on the Company
and Citibank and/or its nominee in the absence of demonstrable error) the
Company will pay the amount of such shortfall to Citibank or its nominee in cash
in immediately available funds.

SECTION 2.04 Nature of Registrable Securities Citibank acknowledges that the
Registrable Securities will, when issued to it, be "restricted securities" under
the 1933 Act and may not be resold absent compliance with Section 2.03 or
Article 3.

SECTION 2.05 Maintenance of Collateral Value Throughout the continuance of this
Agreement and in consideration of having no other operating covenants or
restrictions related to ALICA, the Company covenants and agrees that it will
cause its Subsidiary, Aetna International, Inc. the controlling shareholder of
ALICA, to maintain the ALICA in such a manner that the fair market value of the
Collateral (the "Collateral Value"), as may be determined by an
internationally-recognized independent appraisal company reasonably selected by
the Company, will not fall below $175 million (the "Minimum Value"). Immediately
upon receipt of notice from pursuant to Clause 2.1 above that Citibank has
elected to exercise it right of sale, the Company will furnish Citibank with a
estimate of the Collateral Value. If this estimate indicates that Aetna is not
in compliance with the covenant contained in the first sentence of this Clause
(i.e. the estimate is less than the Minimum Value), then in lieu of any other
determination of damages resulting from such non-compliance and in liquidation
of any such damages the amount

                                       4
<PAGE>   5
payable to Citibank pursuant to Clause 2.1 shall be the Lender Default Amount,
without regard to the Collateral Value.

SECTION 2.06 No Default or Acceleration The Company's obligation to make payment
under this Article 2, if timely made, shall not be deemed to be an event of
default or acceleration of an obligation of Company, notwithstanding the
existence of an Event of Default with respect to the Borrower's obligations or a
determination of non-compliance pursuant to Clause 2.05 above.

                                    ARTICLE 3

                               REGISTRATION RIGHTS

       SECTION 3.01. Shelf Registration. (a) Promptly following receipt of a
notice from Citibank or its nominee under Section 2.03(b), the Company shall
prepare and file with the Commission a shelf registration statement (as amended
and supplemented from time to time, the "SHELF REGISTRATION STATEMENT") relating
to the Registrable Securities in accordance with Rule 415 under the 1933 Act and
will use its best efforts to cause such Shelf Registration Statement to be
declared effective no later than the date which is forty-five (45) days from the
date of such notice under Section 2.03(b) and, subject to Section 6.01 hereof,
to keep such Shelf Registration Statement continuously effective and in
compliance with the 1933 Act and usable for resale of such Registrable
Securities, for the greater of (a) a period from the date on which the
Commission declares such Shelf Registration Statement effective until the first
date upon which the aggregate amount of Registrable Securities then owned by
Citibank or its nominee could be sold without restriction as to amount or manner
of sale pursuant to Rule 144 under the 1933 Act within 15 trading days or (b)
for at least a period of sixty (60) days; provided, however, that such 60-day
period shall be extended for a period of time equal to the period Citibank or
its nominee refrains from selling any securities included in such registration
at the request of an underwriter of Common Stock (or other securities) engaged
by the Company.

       (b) If the aggregate proceeds from an offering of Registrable Securities
pursuant to the Shelf Registration Statement are expected to be more than $100
million and if Citibank or its nominee so elects, such offering may be in the
form of an underwritten offering. Citibank or its nominee shall select the
managing Underwriters and any additional investment bankers and managers to be
used in connection with such offering; provided that such managing Underwriters
and additional investment bankers must be reasonably satisfactory to the
Company.

       SECTION 3.02. Piggyback Registration. If the Company proposes to file a
registration statement under the 1933 Act with respect to an offering of Common
Stock (i) for the Company's own account (other than a registration statement on
Form S-4 or S-8 (or any substitute form that may be adopted by the Commission))
or (ii) for the account of any of its holders of Common Stock, then the Company
shall give written notice of such proposed filing to Citibank or its nominee as
soon as practicable (but in no event less than 10 days before the anticipated
filing date), and such notice shall offer Citibank or its nominee the
opportunity to register such number

                                       5
<PAGE>   6
of shares of Registrable Securities as Citibank or its nominee may request on
the same terms and conditions as the Company's or such holder's Common Stock (a
"PIGGYBACK REGISTRATION").

       SECTION 3.03. Reduction of Offering. Notwithstanding anything contained
herein, if the managing Underwriter of an offering described in Section 3.02
delivers a written opinion to the Company that (i) the size of the offering that
Citibank, the Company and any other Persons intend to make or (ii) the
combination of securities that Citibank, the Company and such other Persons
intend to include in such offering are such that the success of the offering
would be materially and adversely affected, then (A) if the size of the offering
is the basis of such Underwriter's opinion, the amount of Registrable Securities
to be offered for the account of Citibank shall be reduced to the extent
necessary to reduce the total amount of securities to be included in such
offering to the amount recommended by such managing Underwriter; provided that
in the case of a Piggyback Registration, if securities are being offered for the
account of Persons other than the Company, then the proportion by which the
amount of such Registrable Securities intended to be offered for the account of
Citibank is reduced shall not exceed the proportion by which the amount of such
securities intended to be offered for the account of such other Persons is
reduced; and (B) if the combination of securities to be offered is the basis of
such Underwriter's opinion, (x) the Registrable Securities to be included in
such offering shall be reduced as described in clause (A) above (subject to the
proviso in clause (A)), and (y) if the actions described in sub-clause (x) of
this clause (B) would, in the judgment of the managing Underwriter, be
insufficient substantially to eliminate the adverse effect that inclusion of the
Registrable Securities requested to be included would have on such offering,
such Registrable Securities will be excluded from such offering.

       SECTION 3.04. Sale following registration. Citibank agrees, and agrees to
cause its nominee to use all reasonable efforts to sell all the Registrable
Securities promptly after the effective date of any relevant registration
referred to in this Article 3 and to apply the proceeds of any such sale in or
towards satisfaction of the Lender Default Amount. Where the proceeds of such
sale exceed the Lender Default Amount, Citibank will promptly pay such excess
amount to the Company in cash in immediately available funds and return to the
Company any residual Registrable Securities held by Citibank or its nominee. If
on the earlier of (i) the date Citibank and/or its nominee have sold all of the
Registrable Securities or (ii) on hundred and twenty (120) days following the
date of notice from Citibank pursuant to Section 2.03(b), if the aggregate
proceeds received by Citibank and its nominee(s) from any sale of Registrable
Securities is less than the Lender Default Amount (including in circumstances
where the Registrable Securities have not all been sold within 120 days as
above), then promptly following receipt of a certificate from Citibank or its
nominee stating the amount of such shortfall (which shortfall shall be the
amount required, after applying any sales proceeds, to ensure Citibank receives
the Lender Default Amount, such certificate shall be binding on the Company and
Citibank and its nominee(s) in the absence of demonstrable error) the Company
will pay the amount of such shortfall to Citibank or its nominee in cash in
immediately available funds and if applicable, Citibank will return to the
Company any residual Registrable Securities held by Citibank or its nominee.

                                    ARTICLE 4

                             REGISTRATION PROCEDURES

                                       6
<PAGE>   7
         SECTION 4.01. Filings; Information. In connection with the Shelf
Registration Statement pursuant to Section 3.01 hereof, the Company and Citibank
agree as follows:

       (a) Citibank will notify Company at least l0 days prior to making any
offer or sale of any Registrable Securities pursuant to the Shelf Registration
Statement. The Company shall be entitled, by notifying Citibank within 5 days of
receiving the aforementioned notice from the Citibank, to postpone or suspend
for a reasonable period of time (in no event to exceed 75 days) the offering of
any Registrable Securities if the Company shall determine in good faith that
such offering will interfere with a pending or contemplated financing, merger,
sale or acquisition of assets, recapitalization or other corporate action or
policies of the Company. If the Company elects to so postpone or suspend the
offering of any Registrable Securities, the Company shall, to the extent
necessary, amend or supplement the Shelf Registration Statement to permit the
offering of Registrable Securities within 75 days of receiving the
aforementioned notice from the Citibank.

       (b) The Company will, if requested, prior to filing the Shelf
Registration Statement or any amendment or supplement thereto (but not including
any document incorporated by reference in the Shelf Registration Statement),
furnish to Citibank or its nominee and each applicable managing Underwriter, if
any, without charge, copies thereof, and thereafter furnish to Citibank or its
nominee and each such Underwriter, if any, without charge, such number of copies
of such registration statement, amendment and supplement thereto (including all
exhibits thereto and any document incorporated by reference in the Shelf
Registration Statement) and the prospectus included in such registration
statement (including each preliminary prospectus) as Citibank or its nominee or
each such Underwriter may reasonably request in order to facilitate the sale of
the Registrable Securities.

       (c) After the filing of the Shelf Registration Statement, the Company
will promptly notify Citibank or its nominee of any stop order issued or, to the
Company's knowledge, threatened to be issued by the Commission and use its best
efforts to prevent the entry of such stop order or to remove it if entered at
the earliest possible date.

       (d) The Company will use its best efforts in cooperation with Citibank or
its nominee and the Underwriters or agents, as the case may be, to qualify the
Registrable Securities for offer and sale under such other securities or blue
sky laws of such jurisdictions in the United States as Citibank or its nominee
reasonably requests; provided that the Company will not be required to (i)
qualify generally to do business in any jurisdiction where it would not
otherwise be required to qualify but for this paragraph (d), (ii) subject itself
to taxation in any such jurisdiction or (iii) consent to general service of
process in any such jurisdiction.

       (e) At any time when a prospectus relating to the sale of the Registrable
Securities is required by law to be delivered in connection with sales by an
Underwriter or dealer, the Company will as promptly as is practicable notify
Citibank or its nominee of the occurrence of any event requiring the preparation
of a supplement or amendment to such prospectus so that, as thereafter delivered
to the purchasers of such Registrable Securities, such prospectus will not
contain an untrue statement of a material fact or omit to state any material
fact required to be

                                       7
<PAGE>   8
stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading and shall as promptly
as practicable make available to Citibank or its nominee and to the Underwriters
any such supplement or amendment. Citibank agrees that, upon receipt of any
notice from the Company of the occurrence of any event of the kind described in
the preceding sentence, Citibank or its nominee will forthwith discontinue the
offer and sale of Registrable Securities pursuant to the registration statement
covering such Registrable Securities until receipt by Citibank or its nominee
and the Underwriters of the copies of such supplemented or amended prospectus
and, if so directed by the Company, Citibank or its nominee will deliver to the
Company all copies, other than permanent file copies then in Citibank's or its
nominee's possession, of the most recent prospectus covering such Registrable
Securities at the time of receipt of such notice.

       (f) The Company will deliver to Citibank or its nominee and each
Underwriter or agent participating in an offering pursuant to the Shelf
Registration Statement, without charge, as many copies of each preliminary
prospectus as Citibank or its nominee or such Underwriter or agent may
reasonably request, and the Company hereby consents to the use of such copies
for purposes permitted by the 1933 Act. The Company will deliver to Citibank or
its nominee and each Underwriter or agent participating in such offering,
without charge, from time to time during the period when a prospectus is
required to be delivered under the 1933 Act, such number of copies of such
prospectus (as supplemented or amended) as Citibank or its nominee or such
Underwriter or agent may reasonably request.

       (g) The Company will comply with the 1933 Act and the rules and
regulations of the Commission thereunder, and the 1934 Act and the rules and
regulations of the Commission thereunder so as to permit the completion of the
distribution of the Registrable Securities pursuant to the Shelf Registration
Statement in accordance with the intended method or methods of distribution
contemplated in the prospectus relating thereto.

       (h) Upon the request of Citibank or its nominee or the managing
Underwriter or agent, as the case may be, or if required by the rules,
regulations or instructions applicable to the registration form used by the
Company, or by the 1933 Act or by any other rules and regulations thereunder in
connection with the offering of Registrable Securities pursuant to the Shelf
Registration Statement, the Company will prepare a prospectus supplement that
complies with the 1933 Act and the rules and regulations of the Commission
thereunder and that sets forth the aggregate amount of the Registrable
Securities being sold, the name or names of any Underwriters or agents
participating in the offering, the price at which the Registrable Securities are
to be sold, any discounts, commissions or other items constituting compensation,
and such other information as Citibank or the managing Underwriter or agent, as
the case may be, and the Company deem appropriate in connection with the
offering of the Registrable Securities prior to its being used or filed with the
Commission.

       (i) The Company may require Citibank or its nominee to promptly furnish
in writing to the Company such information regarding the distribution of the
Registrable Securities as may be legally required in connection with such
registration.

       (j) The Company will enter into customary agreements (including an
underwriting

                                       8
<PAGE>   9
agreement in customary form) and take such other actions as are reasonably
required in order to expedite or facilitate the sale of such Registrable
Securities.

       (k) The Company will furnish to Citibank or its nominee and to each
Underwriter a signed counterpart, addressed to Citibank or its nominee or such
Underwriter, of (i) an opinion or opinions of counsel to the Company and (ii) a
comfort letter or comfort letters from the Company's independent public
accountants, each in customary form and covering such matters of the type
customarily covered by opinions or comfort letters, as the case may be, as
Citibank or its nominee or the managing Underwriter reasonably requests.

       (l) The Company will file any reports required to be filed by it under
the 1933 Act and the 1934 Act and the rules and regulations of the Commission
thereunder.

       (m) The Company will use its reasonable efforts to cause all such
Registrable Securities to be listed on each securities exchange on which similar
securities issued by the Company are then listed.

       SECTION 4.02. Registration Expenses. In connection with the Shelf
Registration Statement and in connection with any Piggyback Registration, the
Company shall pay the following expenses incurred in connection with such
registration: (i) filing fees with the Commission, (ii) fees and expenses of
compliance with securities or blue sky laws (including reasonable fees and
disbursements of counsel in connection with blue sky qualifications of the
Registrable Securities), (iii) printing expenses, (iv) fees and expenses
incurred in connection with the listing of the Registrable Securities, (v) fees
and expenses of counsel and independent certified public accountants for the
Company; (vi) the reasonable fees and expenses of any additional experts
retained by the Company in connection with such registration; and (vii) any
underwriting fees, discounts or commissions attributable to the sale of
Registrable Securities and any out-of-pocket expenses of Citibank.

       SECTION 4.03 Offering Proceeds and Release of Citibank The Company and
Citibank agree that the number of Registrable Securities shall be determined
based on the Company's reasonable estimate of the amount of such Securities that
must be registered in order to provide Citibank with net sale proceeds equal to
the Lender Default Amount. Under no circumstances will the Company be obligated
to issue Citibank more than 3,200,000 shares of Registrable Securities.
Immediately upon receipt of proceeds from the sale of Registrable Securities and
cash payments from the Company in the aggregate amount of the Lender Default
Amount, Citibank shall provide the Company with written acknowledgement of the
satisfaction and release in full of all obligations of the Company to Citibank
under this Agreement.

                                    ARTICLE 5

                        INDEMNIFICATION AND CONTRIBUTION

       SECTION 5.01. Indemnification by the Company. The Company agrees to
indemnify and hold harmless Citibank, its officers and directors, and each
Person, if any, who controls Citibank within the meaning of either Section 15 of
the 1933 Act or Section 20 of the 1934 Act from and

                                       9
<PAGE>   10
against any and all losses, claims, damages and liabilities (or actions in
respect thereof) caused by any untrue statement or alleged untrue statement of a
material fact contained in any registration statement or prospectus relating to
the Registrable Securities (as amended or supplemented if the Company shall have
furnished any amendments or supplements thereto) or any preliminary prospectus,
offering circular, or other document (including any related registration
statement, notification, or the like) incident to any such registration,
qualification or compliance, or caused by any omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, except insofar as such losses, claims,
damages or liabilities are caused by any such untrue statement or omission or
alleged untrue statement or omission based upon information, relating to
Citibank or the plan of distribution furnished in writing to the Company by or
on behalf of Citibank expressly for use therein; and the Company will pay to
Citibank, each of its officers and directors, or controlling person, any legal
or other expenses reasonably incurred by them in connection with investigating
or defending any such expense, loss, claim, damage, liability or action;
provided, however, that the foregoing indemnity agreement shall not apply to
amounts paid in settlement of any such expense, loss, claim, damage, liability
or action if such settlement is effected without the consent of the Company
(which consent shall not be unreasonably withheld), nor shall the foregoing
indemnity agreement inure to the benefit of Citibank with respect to any
preliminary prospectus if a copy of the most current prospectus at the time of
the delivery of the Registrable Securities was not provided to any purchaser and
such current prospectus would have cured the defect giving rise to such loss,
claim, damage or liability and was in fact previously furnished to the Citibank
and the managing Underwriters, if any, in quantities sufficient to deliver the
same to all such purchasers. The Company also agrees to indemnify any
Underwriters of the Registrable Securities, their officers and directors and
each person who controls such Underwriters on substantially the same basis as
that of the indemnification of Citibank provided in this Section 5.01.

       SECTION 5.02. Indemnification by Citibank. Citibank agrees to indemnify
and hold harmless the Company, its officers and directors, and each Person, if
any, who controls the Company within the meaning of either Section 15 of the
1933 Act or Section 20 of the 1934 Act to the same extent as the foregoing
indemnity from the Company to Citibank, but only with reference to information
relating to Citibank or the plan of distribution furnished in writing by or on
behalf of Citibank expressly for use in any registration statement or prospectus
relating to the Registrable Securities (as amended or supplemented if the
Company shall have furnished any amendments or supplements thereto) or any
preliminary prospectus. Citibank also agrees to indemnify and hold harmless any
Underwriters of the Registrable Securities, their officers and directors and
each person who controls such Underwriters on substantially the same basis as
that of the indemnification of the Company provided in this Section 5.02.

       SECTION 5.03. Conduct of Indemnification Proceedings. In case any
proceeding (including any governmental investigation) shall be instituted
involving any Person in respect of which indemnity may be sought pursuant to
Section 5.01 or Section 5.02, such Person (the "INDEMNIFIED PARTY") shall
promptly notify the Person against whom such indemnity may be sought (the
"INDEMNIFYING PARTY") in writing; and the Indemnifying Party, upon the request
of the Indemnified Party, shall retain counsel reasonably satisfactory to such
Indemnified Party to represent such Indemnified Party and any others the
Indemnifying Party may designate in such

                                       10
<PAGE>   11
proceeding and shall pay the fees and disbursements of such counsel related to
such proceeding. In any such proceeding, any Indemnified Party shall have the
right to retain its own counsel, but the fees and expenses of such counsel shall
be at the expense of such Indemnified Party unless (i) the Indemnifying Party
and the Indemnified Party shall have mutually agreed to the retention of such
counsel or (ii) the named parties to any such proceeding (including any
impleaded parties) include both the Indemnified Party and the Indemnifying Party
and representation of both parties by the same counsel would be inappropriate
due to actual or potential differing interests between them. It is understood
that the Indemnifying Party shall not, in connection with any proceeding or
related proceedings in the same jurisdiction, be liable for the fees and
expenses of more than one separate firm of attorneys (in addition to any local
counsel) at any time for all such Indemnified Parties, and that all such fees
and expenses shall be reimbursed as they are incurred. In the case of any such
separate firm for the Indemnified Parties, such firm shall be designated in
writing by the Indemnified Parties. The Indemnifying Party shall not be liable
for any settlement of any proceeding effected without its written consent, but
if settled with such consent, or if there be a final judgment for the plaintiff,
the Indemnifying Party shall indemnify and hold harmless such Indemnified
Parties from and against any loss or liability (to the extent stated above) by
reason of such settlement or judgment.

       SECTION 5.04. Contribution. (a) If the indemnification provided for in
this Article 5 is unavailable to an Indemnified Party in respect of any losses,
claims, damages or liabilities referred to herein, then in lieu of such
indemnification (i) as between the Company, on the one hand, and Citibank, on
the other hand, the Company and Citibank shall contribute to the aggregate
losses, liabilities, claims, damages and expenses of the nature contemplated by
such indemnity incurred by the Company and Citibank, as incurred, in such
proportion as is appropriate to reflect the relative fault of the Company, on
the one hand, and of Citibank, on the other hand, in connection with the
statements or omissions which resulted in such losses, liabilities, claims,
damages or expenses, as well as any other relevant equitable considerations and
(ii) as between the Company and Citibank, on the one hand, and the Underwriters
or agents, on the other hand, the Company, Citibank, Underwriters and agents
shall contribute to such aggregate losses, liabilities, claims, damages and
expenses in proportion such that (x) the Underwriters and agents are responsible
for that portion represented by the percentage that the underwriting discounts
and commissions for the offering appearing on the cover page of the relevant
prospectus (or, if not set forth on the cover page, that are applicable to the
relevant offering) bear to the initial public offering price appearing on the
cover page (or, if not set forth on the cover page, that are applicable to the
offering), and (y) Citibank and the Company are responsible to contribute pro
rata, based upon the amount of net proceeds realized by each, in respect of the
balance.

       (b) The relative fault of the Company on the one hand and Citibank on the
other hand shall be determined by reference to, among other things, whether any
such untrue or alleged untrue statement of a material fact or omission or
alleged omission to state a material fact relates to information supplied by the
Company or by Citibank and the parties' relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.

       (c) The Company and Citibank agree that it would not be just and
equitable if

                                       11
<PAGE>   12
contribution pursuant to this Section 5.04 were determined by pro rata
allocation or by any other method of allocation that does not take account of
the equitable considerations referred to in Section 5.04 (a). The amount paid or
payable by an Indemnified Party as a result of the losses, claims, damages or
liabilities referred to in Section 5.04(a) shall be deemed to include, subject
to the limitations set forth above, any legal or other expenses reasonably
incurred by such Indemnified Party in connection with investigating or defending
any such action or claim. Notwithstanding the provisions of this Article 5, no
Underwriter shall be required to contribute any amount in excess of the amount
by which the total price at which the Securities underwritten by it and
distributed to the public were offered to the public exceeds the amount of any
damages which such Underwriter has otherwise been required to pay by reason of
such untrue or alleged untrue statement or omission or alleged omission, and
Citibank shall not be required to contribute any amount in excess of the amount
by which the net proceeds of the offering (before deducting expenses) received
by Citibank exceeds the amount of any damages which Citibank has otherwise been
required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission. No person guilty of fraudulent misrepresentation (within
the meaning of Section 1l(f) of the 1933 Act) shall be entitled to contribution
from any Person who was not guilty of such fraudulent misrepresentation.

                                    ARTICLE 6

                             LOAN AGREEMENT PURCHASE

       SECTION 6.01. Loan Agreement Purchase. At any time during which this
Agreement remains in effect, the Company shall have the right to purchase, or to
cause its nominee to purchase, from Citibank all of Citibank's rights, benefits
and obligations under or arising out of the Loan Agreement and all Ancillary
Agreements upon (i) at least fifteen (15) days prior notice to Citibank and (ii)
payment to Citibank an amount equal to all unpaid principal, accrued interest,
costs and other amounts due and owing to Citibank by Ta Hsing as certified by
Citibank (whose certification shall be conclusive and binding on the Company and
Citibank in the absence of demonstrable error). Upon completion of such
purchase, Citibank shall assign to the Company (or its nominee) all rights of
Citibank under the Loan Agreement, this Agreement, and all Ancillary Agreements.

       SECTION 6.02. Notice of Default. Citibank shall notify the Company
promptly of any Event of Default or Potential Event of Default under the Loan
Agreement (as those terms are defined therein). If within five (5) days of
receipt of such notice the Company provides Citibank with a binding written
indication that the Company will either (i) purchase Citibank's rights, benefits
and obligations under or arising out of the Loan Agreement and all Ancillary
Documents pursuant to Section 6.01 above or (ii) cure the Event of Default to
Citibank's satisfaction (assuming such Event of Default can be cured and within
the relevant cure period specified in that Event of Default), then Citibank will
refrain from declaring such Event of Default or Potential Event of Default under
the Loan Agreement pending the purchase or cure.

                                    ARTICLE 7

                                       12
<PAGE>   13
                  REPRESENTATIONS AND WARRANTIES OF THE COMPANY

       The Company represents and warrants as follows:

       SECTION 7.01. Corporate Existence and Power. The Company (i) is a
Connecticut corporation duly incorporated, validly existing as a corporation and
in good standing under the laws of the State of Connecticut, (ii) has all
corporate powers required to issue, sell and deliver the Registrable Securities
and to perform its other obligations pursuant hereto and (iii) has all
governmental licenses, authorizations, consents and approvals required to carry
on its business as now conducted, the failure to obtain which would,
individually or in the aggregate, have a material adverse effect on its ability
to perform its obligations hereunder or on the financial condition of the
Company and its Subsidiaries taken as a whole.

       SECTION 7.02. Corporate and Governmental Authorization; No Contravention.
The execution, delivery and performance by the Company of this Agreement, the
consummation of the transactions contemplated hereby by the Company and the
issuance of the Registrable Securities in accordance with the terms hereof by
the Company are within its corporate powers, have been duly authorized by all
necessary corporate action, require no action by or in respect of, or advance
filing with, any governmental body, agency or official (except as may be
required under applicable securities laws, including the 1933 Act, the 1934 Act,
and applicable state securities or "blue sky" laws) and do not contravene, or
constitute a default under, (i) any provision of the certificate of
incorporation or by-laws of the Company, (ii) any applicable law or regulation
or any judgment, injunction, order or decree binding upon the Company, or (iii)
any material financial agreement or instrument (excluding insurance obligations)
of the Company. In addition, this Agreement has been duly executed and delivered
by the Company.

       SECTION 7.03. Binding Effect. This Agreement constitutes a valid and
binding agreement of the Company and is enforceable in accordance with its terms
except as may be limited by bankruptcy, insolvency, reorganization, moratorium
or similar laws affecting the enforcement of creditors' rights generally and by
general principles of equity.

       SECTION 7.04. Issuance of Common Stock. The issuance, sale and delivery
of the Common Stock in accordance with this Agreement has been duly authorized
by all requisite corporate action on the part of the Company, and the Common
Stock, when so issued and delivered in accordance with the provisions of this
Agreement will be duly and validly issued, fully paid and nonassessable.

       SECTION 7.05. Solvency. The Company and the Company and its Subsidiaries,
on a consolidated basis, are Solvent. For the purposes of this Section,
"Solvent" means, with respect to any Person on a particular date, that on such
date (a) the fair value of the property of such Person is greater than the total
amount of liabilities, including, without limitation, contingent liabilities, of
such Person, (b) the present fair salable value of the assets of such Person is
not less than the amount that will be required to pay the probable liability of
such Person on its debts as they become absolute and matured, (c) such Person
does not intend to, and does not believe that it will, incur debts or
liabilities beyond such Person's ability to pay such debts and liabilities as

                                       13
<PAGE>   14
they mature and (d) such Person is not engaged in business or a transaction, and
is not about to engage in business or a transaction, for which such Person's
property would constitute an unreasonably small capital. The amount of
contingent liabilities at any time shall be computed as the amount that, in the
light of all the facts and circumstances existing at such time, represents the
amount that can reasonably be expected to become an actual or matured liability.

       SECTION 7.06. No Material Adverse Change. Except as disclosed in the
Company's 1999 Form 10-Q, since 30 September, 1999, there has been no material
adverse change in the business, financial position or results of operations of
the Company and its Consolidated Subsidiaries, taken as a whole.

SECTION 7.07. Continuing Representation and Warranty. The Company also
represents and warrants to and undertakes with Citibank that the foregoing
representations and warranties (other than those in Sections 7.05 and 7.06) will
be true and accurate throughout the continuance of this Agreement with reference
to the facts and circumstances subsisting from time to time.

                                    ARTICLE 8
                                  MISCELLANEOUS

       SECTION 8.01. Participation in Underwritten Registrations. No Person may
participate in any underwritten registered offering contemplated hereunder
unless such Person (a) agrees to sell its securities on the basis provided in
any underwriting arrangements approved by the Persons entitled hereunder to
approve such arrangements and (b) completes and executes all questionnaires,
powers of attorney, underwriting agreements and other documents reasonably
required under the terms of such underwriting arrangements or this Agreement.

       SECTION 8.02. Rule 144. The Company covenants that it will file any
reports required to be filed by it under the 1933 Act and the 1934 Act and that
it will take such further action as Citibank may reasonably request to the
extent required from time to time to enable Citibank or its nominee to sell
Registrable Securities without registration under the 1933 Act within the
limitation of the exemptions provided by Rule 144 under the 1933 Act, as such
Rule may be amended from time to time, or any similar rule or regulation
hereafter adopted by the Commission. Upon the request of Citibank, the Company
will deliver to Citibank (i) a written statement as to whether it has complied
with such reporting requirements (ii) a copy of the most recent annual or
quarterly report of the Company and such other reports and documents so filed by
the Company as Citibank may reasonably request, and (iii) such other information
as may be reasonably requested by Citibank in availing Citibank or its nominee
of any rule or regulation of the Commission which permits the selling of any
such Registrable Securities without registration.

         SECTION 8.03. Transfer of Registration Rights. None of the rights of
Citibank under this Agreement shall be assignable by Citibank except as provided
in Section 8.06 hereof.

         SECTION 8.04. Notices. All notices, requests and other communications
to either party hereunder shall be in writing (including telecopy or similar
writing) and shall be given,

                                       14
<PAGE>   15
if to the Company, to:
       Aetna Inc.
       151 Farmington Avenue,
       Hartford, CT 06156

with a copy to:
       Aetna Inc.
       Office of the Corporate Secretary
       151 Farmington Avenue
       Hartford, CT 06156
       Telecopier No.: (860) 273-8340
       Attention:   William J. Casazza, Esq.

and
       Davis Polk & Wardwell
       450 Lexington Avenue
       New York, NY 10017
       Telecopier No.: (212) 450-4800
       Attention:   David L. Caplan, Esq.

                                       15
<PAGE>   16
if to Citibank, to:
       Citibank, N.A.
       399 Park Avenue
       New York, NY  10043
       Telecopier No.: (212) 935-4285
       Attention:   Maria Hackley

and to any nominee which Citibank may use to hold Registrable Securities in
which case notices shall be sent to such address as shall be notified by
Citibank to the Company in writing,

or such other address or telecopier number as such party may hereafter specify
for the purpose by notice to the other party hereto. Each such notice, request
or other communication shall be effective when delivered at the address
specified in this Section 8.04.

       SECTION 8.05. Amendments; No Waivers. (a) Any provision of this Agreement
may be amended or waived if, and only if, such amendment or waiver is in writing
and signed, in the case of an amendment, by Citibank and the Company, or in the
case of a waiver, by the party against whom the waiver is to be effective.

       (b) No failure or delay by any party in exercising any right, power or
privilege hereunder shall operate as a waiver thereof nor shall any single or
partial exercise thereof preclude any other or future exercise thereof or the
exercise of any other right, power or privilege. The rights and remedies herein
provided shall be cumulative and not exclusive of any rights or remedies
provided by law.

       SECTION 8.06. Successors and Assigns. The provisions of this Agreement
shall be binding upon and inure to the benefit of the parties hereto and their
respective successors and assigns (it being understood that the rights of
Citibank hereunder may be assigned only to a successor corporation or any
wholly-owned subsidiary of Citibank; provided, that no such assignment shall
relieve Citibank of its obligations hereunder). Neither this Agreement nor any
provision hereof is intended to confer upon any Person other than the parties
hereto and their respective successors and permitted assigns any rights or
remedies hereunder.

       SECTION 8.07. Counterparts; Effectiveness. This Agreement may be signed
in any number of counterparts, each of which shall be an original, with the same
effect as if the signatures thereto and hereto were upon the same instrument.
This Agreement shall become effective when each party hereto shall have received
a counterpart hereof signed by the other party hereto.

       SECTION 8.08. Entire Agreement. This Agreement constitutes the entire
agreement between the parties with respect to the subject matter hereof and
supersedes all prior agreements, understandings and negotiations, both written
and oral, between the parties with respect thereto. No representation,
inducement, promise, understanding, condition or warranty not set forth herein
or therein has been made or relied upon by any of the parties hereto.

                                       16
<PAGE>   17
         SECTION 8.09. Governing Law. This Agreement shall be construed in
accordance with and governed by the laws of the State of New York, without
regard to the conflicts of law rules of such state.

       IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed as of the day and year first above written.

AETNA INC.

By:       /s/ Alan J. Weber
          ---------------------------------------------
     Name:        Alan J. Weber
     Title:       Vice Chairman

CITIBANK, N.A.

By:       /s/ Daniel Brill
          ---------------------------------------------
     Name:        Daniel Brill
     Title:       Vice President

The undersigned Ta Hsing Corp. Limited, a Liberian corporation, acknowledges the
terms of this Agreement and agrees to cooperate with the Company and Citibank in
taking all actions necessary or desirable to give effect to its terms.

Ta Hsing Corp. Limited

By:       /s/ Lee Chao-Hsiang
          ---------------------------------------------
     Name:        Lee Chao-Hsiang
     Title:       Director

                                       17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00002-of-00352.parquet"}]]